Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEMDNASDAQ:BJDXNASDAQ:NXGLNASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$0.41+12.0%$0.38$0.24▼$1.25$6.59M1.932.41 million shs1.13 million shsBJDXBluejay Diagnostics$1.78+1.7%$2.98$1.46▼$316.92$986K0.4489,496 shs60,077 shsNXGLNEXGEL$2.72+5.0%$2.74$1.84▼$5.10$20.82M0.6566,880 shs76,964 shsVVOSVivos Therapeutics$3.14+4.7%$2.83$1.91▼$6.28$18.50M7.31451,910 shs71,663 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical+12.02%+7.61%+19.22%-39.87%-65.25%BJDXBluejay Diagnostics+2.22%+1.71%-32.58%-51.23%-99.11%NXGLNEXGEL+5.02%+4.21%+7.09%-16.82%+23.81%VVOSVivos Therapeutics+4.32%+20.31%+34.76%-20.30%+47.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEMDAethlon Medical2.9882 of 5 stars3.55.00.00.02.60.01.3BJDXBluejay Diagnostics0.42 of 5 stars0.02.00.00.03.30.00.6NXGLNEXGEL1.3703 of 5 stars0.05.00.00.02.82.50.0VVOSVivos Therapeutics2.4186 of 5 stars3.55.00.00.01.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical 3.00Buy$7.001,607.32% UpsideBJDXBluejay Diagnostics 0.00N/AN/AN/ANXGLNEXGEL 0.00N/AN/AN/AVVOSVivos Therapeutics 3.00Buy$6.1094.27% UpsideCurrent Analyst Ratings BreakdownLatest AEMD, BJDX, NXGL, and VVOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2025VVOSVivos TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.60 ➝ $6.204/1/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/10/2025AEMDAethlon MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.002/19/2025AEMDAethlon MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon Medical$570K11.55N/AN/A$2.19 per share0.19BJDXBluejay Diagnostics$250K3.94N/AN/A$934.50 per share0.00NXGLNEXGEL$8.69M2.40N/AN/A$0.90 per share3.02VVOSVivos Therapeutics$15.03M1.23N/AN/A$0.22 per share14.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$12.21M-$1.58N/AN/AN/AN/A-153.96%-109.13%6/26/2025 (Estimated)BJDXBluejay Diagnostics-$9.95M-$772.37N/A∞N/AN/A-155.67%-117.82%5/21/2025 (Estimated)NXGLNEXGEL-$3.16M-$0.50N/A∞N/A-52.60%-71.19%-34.79%N/AVVOSVivos Therapeutics-$13.58M-$2.91N/AN/AN/A-86.19%-335.04%-93.58%5/13/2025 (Estimated)Latest AEMD, BJDX, NXGL, and VVOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025VVOSVivos Therapeutics-$0.41N/AN/AN/A$3.63 millionN/A3/31/2025Q4 2024BJDXBluejay Diagnostics-$36.00-$112.37-$76.37-$112.37N/AN/A3/27/2025Q4 2024VVOSVivos Therapeutics-$0.43-$0.28+$0.15-$0.28$3.89 million$3.70 million3/24/2025Q4 2024NXGLNEXGEL-$0.10-$0.08+$0.02-$0.11$2.99 million$3.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/ABJDXBluejay DiagnosticsN/AN/AN/AN/AN/ANXGLNEXGELN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A2.802.80BJDXBluejay DiagnosticsN/A6.266.26NXGLNEXGEL0.191.510.93VVOSVivos TherapeuticsN/A1.441.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%BJDXBluejay Diagnostics18.47%NXGLNEXGEL2.21%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipAEMDAethlon Medical1.10%BJDXBluejay Diagnostics0.37%NXGLNEXGEL24.86%VVOSVivos Therapeutics3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical1016.06 million14.30 millionNo DataBJDXBluejay Diagnostics9554,000551,000Not OptionableNXGLNEXGEL107.65 million5.10 millionNot OptionableVVOSVivos Therapeutics1605.89 million5.71 millionOptionableAEMD, BJDX, NXGL, and VVOS HeadlinesRecent News About These CompaniesVivos Therapeutics (VVOS) Expected to Announce Earnings on TuesdayMay 12 at 1:47 AM | americanbankingnews.comVivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 6, 2025 | zacks.comVivos to acquire sleep centerApril 17, 2025 | hmenews.comVivos Therapeutics announces agreement to acquire operating assets of SCNApril 17, 2025 | markets.businessinsider.comVivos Opens New Sleep CenterApril 16, 2025 | baystreet.caVivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in NevadaApril 16, 2025 | globenewswire.comVivos Therapeutics price target lowered to $5.50 from $6 at Alliance Global PartnersApril 2, 2025 | markets.businessinsider.comVivos Therapeutics’ Earnings Call Highlights Growth and ExpansionApril 1, 2025 | tipranks.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comVivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comVivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue EstimatesMarch 31, 2025 | zacks.comVivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational UpdateMarch 31, 2025 | globenewswire.com4VVOS : Earnings Outlook For Vivos TherapeuticsMarch 28, 2025 | benzinga.comVivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference CallMarch 28, 2025 | globenewswire.comVivos Therapeutics expands strategic alliance with Rebis HealthFebruary 25, 2025 | markets.businessinsider.comVivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions NationwideFebruary 24, 2025 | markets.businessinsider.comVivos Therapeutics sees strong adoption of OSA treatment, expands strategic allianceFebruary 24, 2025 | proactiveinvestors.comVivos Therapeutics Enters Market Offering Agreement with WainwrightFebruary 14, 2025 | tipranks.comVivos Therapeutics files $50M mixed securities shelfFebruary 11, 2025 | markets.businessinsider.comVivos Therapeutics files to sell 854,332 shares of common stock for holdersJanuary 22, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEMD, BJDX, NXGL, and VVOS Company DescriptionsAethlon Medical NASDAQ:AEMD$0.41 +0.04 (+12.02%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$0.42 +0.01 (+2.44%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.Bluejay Diagnostics NASDAQ:BJDX$1.78 +0.03 (+1.71%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$1.80 +0.02 (+1.12%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.NEXGEL NASDAQ:NXGL$2.72 +0.13 (+5.02%) Closing price 05/12/2025 03:54 PM EasternExtended Trading$2.70 -0.03 (-0.92%) As of 05/12/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.Vivos Therapeutics NASDAQ:VVOS$3.14 +0.14 (+4.67%) Closing price 05/12/2025 03:59 PM EasternExtended Trading$3.15 +0.01 (+0.29%) As of 05/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
